Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment

Valerio Brunetti; Anna Losurdo; Elisa Testani; Leonardo Lapenta; Paolo Mariotti; Camillo Marra; Paolo Maria Rossini; Giacomo Della Marca

doi:10.2174/1567205011666140302195648

Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment

Valerio Brunetti, Anna Losurdo, Elisa Testani, Leonardo Lapenta, Paolo Mariotti, Camillo Marra, Paolo Maria Rossini, Giacomo Della Marca

Istituto San Raffaele Pisana

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.

Original language	English
Pages (from-to)	267-273
Number of pages	7
Journal	Current Alzheimer Research
Volume	11
Issue number	3
DOIs	https://doi.org/10.2174/1567205011666140302195648
Publication status	Published - 2014

Keywords

Acetylcholine
Acetylcholinesterase inhibitors
Alzheimer disease
Cholinergic pathways
MCI
Mild cognitive impairment
RBD
REM
REM behavior disorder
Rivastigmine (RVT)
Sleep

ASJC Scopus subject areas

Neurology
Clinical Neurology

Access to Document

10.2174/1567205011666140302195648

Cite this

@article{7d2db97114104a3cab6adeb0e1011361,

title = "Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment",

abstract = "Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.",

keywords = "Acetylcholine, Acetylcholinesterase inhibitors, Alzheimer disease, Cholinergic pathways, MCI, Mild cognitive impairment, RBD, REM, REM behavior disorder, Rivastigmine (RVT), Sleep",

author = "Valerio Brunetti and Anna Losurdo and Elisa Testani and Leonardo Lapenta and Paolo Mariotti and Camillo Marra and Rossini, {Paolo Maria} and Marca, {Giacomo Della}",

year = "2014",

doi = "10.2174/1567205011666140302195648",

language = "English",

volume = "11",

pages = "267--273",

journal = "Current Alzheimer Research",

issn = "1567-2050",

publisher = "Bentham Science Publishers B.V.",

number = "3",

}

TY - JOUR

T1 - Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment

AU - Brunetti, Valerio

AU - Losurdo, Anna

AU - Testani, Elisa

AU - Lapenta, Leonardo

AU - Mariotti, Paolo

AU - Marra, Camillo

AU - Rossini, Paolo Maria

AU - Marca, Giacomo Della

PY - 2014

Y1 - 2014

N2 - Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.

AB - Background: Mild Cognitive Impairment (MCI) and REM Behavior Disorder (RBD) are both associated with a degeneration of ponto-medullary cholinergic pathways. Methods: We conducted a placebo-controlled, cross-over pilot trial of Rivastigmine (RVT) in 25 consecutive patients with MCI, who presented RBD refractory to conventional first-line treatments (melatonin up to 5 mg/day and clonazepam up to 2 mg/day). Results: RVT treatment was followed by a significant reduction of RBD episodes when compared with placebo. Conclusions: Our data suggest that, in MCI patients with RBD resistant to conventional therapies (muscle relaxants benzodiazepines or melatonin,) treatment with RVT may induce a reduction in the frequency of RBD episodes compared to placebo.

KW - Acetylcholine

KW - Acetylcholinesterase inhibitors

KW - Alzheimer disease

KW - Cholinergic pathways

KW - MCI

KW - Mild cognitive impairment

KW - RBD

KW - REM

KW - REM behavior disorder

KW - Rivastigmine (RVT)

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=84897404975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897404975&partnerID=8YFLogxK

U2 - 10.2174/1567205011666140302195648

DO - 10.2174/1567205011666140302195648

M3 - Article

C2 - 24597506

AN - SCOPUS:84897404975

VL - 11

SP - 267

EP - 273

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1567-2050

IS - 3

ER -

Rivastigmine for refractory REM behavior disorder in Mild Cognitive Impairment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this